Tagged with Pharma

Lithuania Lithuania’s key economic indicators between 2015 and 2018: GDP growth, inflation, unemployment rate, and government budget. Lithuania’s pharma market in terms of both volume and value. Spending on public health in Lithuania. The Lithuanian pharma market split by dispensing types. The public funding of health and pharmaceuticals in Lithuania. Healthcare…

Lithuania The Top 20 pharma companies in Lithuania by value for 2017. J&J leads the way with a value of around EUR 35 million and market share of 6.3% bolstered by 63% year-on-year growth. Berin Chemie ranks second, while Novartis ranks third.

Pharma India leads the way in terms of the sheer volume of US FDA-approved manufacturing plants with over 100, compared to only 28 in China. In terms of the global competitiveness of Brazil, Russia, India, China and South Africa (BRICS), China remained out in front between 2012 and 2015, with India…

Ecuador Efraim Lakierovich, general manager of Celsius in Ecuador, elaborates on the company’s recent internationalization, the unexpected challenges it has faced in the institutional market and his ambitions to grow the affiliate to the point that it surpasses the size of the Uruguayan headquarters. Could you tell our international readers about…

India Vinay Sapte, founder and managing director of Maneesh Pharmaceuticals, provides insights into this company’s unique development path. Maneesh was one of the first Indian companies to establish joint ventures in the US and Europe more than ten years ago and today stands as one of the largest India based partners…

Poland Tomasz Dzitko, founder and CEO of Delfarma, Poland’s leading parallel importer, gives an overview of the sector in Poland and its impact on the healthcare ecosystem, as well as the space for growth in the future, especially via the reimbursement of parallel imported products. Furthermore, he touches on the relationship…

Baltics Janis Biezbardis, chairman and owner of Latvian pharmaceutical wholesaler Farmeko, discusses the evolution of the company’s product portfolio, the receptiveness of the Latvian state to homegrown companies, and Farmeko’s international reach. Could you please start by telling us about the origins of your company? “The Latvian investment board and development…

India Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new…

Ecuador Hector Enriquez, general manager of Laboratorios Industriales Farmaceuticos Ecuadorianos (LIFE), details the flagship Ecuadorian pharmaceutical company’s focus on developing its own market-relevant formulations and the implementation of international manufacturing standards to compete with international pharmaceutical companies in Ecuador. Could you present LIFE Laboratories’ activities and most recent developments in Ecuador?…

Poland Piotr Steczniewski, president of Profarm PS – a successful wholesale family business – since 2012, shares how the company has managed to thrive over the years through constant adaptation to the market and laws. He discusses how strict distribution regulations have been affecting the industry and ultimately advises the government…

India As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus recently received permission to conduct Phase II clinical studies of Lipaglyn, the first drug to treat patients with nonalcoholic steatohepatitis…

Ecuador José Hernández, general manager of CC Laboratories, takes us through the actions he undertook to convert the family run business into a model of operational efficiency. The company increased its sales by a staggering 39% in 2017 and has doubled its profitability over the course of the last three years…